TAFFIC is a fixed dose combination product (three-drug) containing Bictegravir (BIC) 50 mg, Emtricitabine (FTC) 200 mg, Tenofovir Alafenamide (TAF) 25 mg. TAFFIC is indicated for the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL). The recommended dosage of TAFFIC is one tablet taken orally once daily with or without food.
